Pfizer Inc (MIL:1PFE)
€ 24.625 -0.16 (-0.65%) Market Cap: 138.78 Bil Enterprise Value: 192.52 Bil PE Ratio: 34.89 PB Ratio: 1.59 GF Score: 64/100

Pfizer Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 09, 2020 / 05:20PM GMT
Terence C. Flynn
Goldman Sachs Group Inc., Research Division - MD

Great. Good afternoon, everybody. Thank you for joining us. I'm Terence Flynn, the biopharma analyst at Goldman Sachs.

I'm very pleased to welcome Pfizer for this session. Joining us from the company is Chairman and CEO, Albert Bourla. Albert, thank you very much for joining us today, really appreciate your time. And thank you for everything that the company is doing with respect to COVID-19 on both the vaccine and treatment front. I know it's a tremendous effort, and we appreciate everything you're doing.

Albert Bourla
Pfizer Inc. - Chairman & CEO

Thank you very much, Terence, and it's a great privilege and a great responsibility these days to work on a solution.

Questions & Answers

Terence C. Flynn
Goldman Sachs Group Inc., Research Division - MD

Great. Maybe to get started, COVID-19 is obviously going to have near and long-ranging impacts on the system, companies' business models, from delivery of care, clinical trial

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot